Six Therapeutics, Inc.
Howard L. Levine, Ph.D., a proven thought-leader with over 40 years of strategic, operational, and regulatory experience in biopharmaceutical product development and commercialization. Prior to co-founding Six Therapeutics, Dr. Levine was National Leader of the BioProcess Technology Group, a part of the life sciences practice of BDO USA. Throughout his career, Dr. Levine has assisted numerous companies in developing biological products, provided strategic input in the development of new manufacturing technologies, and participated in the successful commercialization of more than ten biopharmaceutical products. In 1994, Dr. Levine founded BioProcess Technology Consultants (BPTC), a leading consulting company that provided integrated strategic, technical, and regulatory advice on biopharmaceutical product development to a broad range of companies. He served as President, and CEO of BPTC until its merger with BDO in 2019. Over the next three years, worked to fully integrate the business into BDO while helping to expand the group and increase revenue over 60%. Retired from BDO in April 2022. Before founding BPTC, Dr. Levine was Vice President of Manufacturing Operations at Repligen Corporation and previously held positions of increasing responsibility in process development and manufacturing at Genentech, Amgen, and Xoma. Dr. Levine is a frequently invited lecturer on manufacturing strategy, downstream processing, and commercialization of biotechnology products and an author of numerous, peer-reviewed publications. In addition to his role as co-founder and CMC lead for Six Therapeutics, Dr. Levine sits on the Scientific Advisory Board of Novel Biologics, Inc., the Board of Advisors of Wheeler Bio, Inc., and the Board of Directors of Triplebar, Inc. He holds a Ph.D. in chemistry from the University of Chicago and completed a post-doctoral fellowship at Harvard University.